TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32665039

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400mg orally once daily for 90 days
Number of subjects: 988

Group type: COMPARATOR
Intervention: Placebo (two tablets visually identical to hydroxychloroquine) orally once daily for 90 days
Number of subjects: 988
Study: 33919991

Group type: EXPERIMENTAL
Intervention: L-carnitine tartrate supplementation
Number of subjects: 0
Study: 33378391

Group type: EXPERIMENTAL
Intervention: High personalized power motive (p Power) leaders
Number of subjects: 96

Group type: COMPARATOR
Intervention: Low personalized power motive (p Power) leaders
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Participants with positive changes in testosterone (T)
Number of subjects: 96
Study: 616115985

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily (n=44)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Matching placebo (n=44)
Number of subjects: 88
Study: 35877933

Group type: EXPERIMENTAL
Intervention: Minimally invasive application of bipolar radiofrequency energy to the affected areas.
Number of subjects: 10
Study: 33920888

Group type: EXPERIMENTAL
Intervention: Heated corn oil (HO)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 2,4-Decadienal (2,4-DD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-heated corn oil (CO)
Number of subjects: 27
Study: 32885874

Group type: EXPERIMENTAL
Intervention: Self-learning (SL) group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Lecture (LS) group
Number of subjects: 114
Study: 36031355

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg (group M)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.5 μg/kg (group H)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg (group L)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 120
Study: 32019389

Group type: EXPERIMENTAL
Intervention: Dance intervention (twice-weekly sessions for 8 months)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 36148447

Group type: EXPERIMENTAL
Intervention: Acupuncture at the sphenopalatine ganglion (SPG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo acupuncture (PA) at the SPG
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rescue medication (RM) only
Number of subjects: 120
Study: 35804455

Group type: EXPERIMENTAL
Intervention: interprof ACT intervention package
Number of subjects: 34
Study: 35036624

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT) once monthly for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home Exercise (HE) for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 0
Study: 36178481

Group type: EXPERIMENTAL
Intervention: MBCT plus psychoeducation
Number of subjects: 148

Group type: COMPARATOR
Intervention: STEP
Number of subjects: 148
Study: 33574445

Group type: EXPERIMENTAL
Intervention: Recall of negative events (mild reinforcement of stress or fear/anxiety)
Number of subjects: 4889

Group type: COMPARATOR
Intervention: Control group (recall of neutral or joyful memories)
Number of subjects: 4889
Study: 32709183

Group type: EXPERIMENTAL
Intervention: 10 kHz high-frequency spinal cord stimulation (HF-SCS)
Number of subjects: 19
Study: 36146310

Group type: EXPERIMENTAL
Intervention: 5 h in bed (03:00‐08:00 h)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 9 h in bed (23:00‐08:00 h)
Number of subjects: 41
Study: 33275162

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 224

Group type: COMPARATOR
Intervention: PAHG
Number of subjects: 224
Study: 33544206

Group type: EXPERIMENTAL
Intervention: 16 g/d native inulin (prebiotic)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 24
Study: 32501247

Group type: EXPERIMENTAL
Intervention: Vertical component ride value for road profile 1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vertical component ride value for road profile 2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined point ride value for road profile 1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined point ride value for road profile 2
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of medians of the relative difference threshold over the two roads
Number of subjects: 10
Study: 32205547

Group type: EXPERIMENTAL
Intervention: Pleth Variability Index (PVI) group
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control group (standard management strategy)
Number of subjects: 438
Study: 35570386

Group type: EXPERIMENTAL
Intervention: MARSI nursing management (risk assessment, risk prevention, and risk management)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: MARSI nursing management
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional nursing care (control group)
Number of subjects: 156
Study: 33017630

Group type: EXPERIMENTAL
Intervention: Intermediate education level
Number of subjects: 12315

Group type: EXPERIMENTAL
Intervention: Advanced education level
Number of subjects: 12315

Group type: EXPERIMENTAL
Intervention: Education (general)
Number of subjects: 12315
Study: 35987728

Group type: EXPERIMENTAL
Intervention: Ozanimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33494132

Group type: EXPERIMENTAL
Intervention: Aronia juice (AJ) with 1177.11 mg polyphenols/100 mL (n = 22)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Aronia juice (MJ) with 294.28 mg polyphenols/100 mL (n = 20)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (PLB) (n = 20)
Number of subjects: 62
Study: 34588230

Group type: EXPERIMENTAL
Intervention: Cultural security training for hospital staff and local, trial-specific, Aboriginal Brain Injury Coordinators supporting participants
Number of subjects: 312
Study: 32799728

Group type: EXPERIMENTAL
Intervention: Gender-based violence (GBV) experienced by FEWs
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Emotional abuse
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Forced substance use
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Physical abuse
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Forced sex
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Victimization by clients
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Victimization by others
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Working in beer gardens
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Working in restaurants/cafés
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Higher acceptance of violence against women
Number of subjects: 600
Study: 32284339

Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham feedback
Number of subjects: 20
Study: 34052458

Group type: EXPERIMENTAL
Intervention: Health literacy evaluation using the Rapid Estimate of Adult Literacy in Medicine (REALM)
Number of subjects: 179
Study: 32843581

Group type: EXPERIMENTAL
Intervention: 24 slip-like treadmill perturbation trials
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 40 slip-like treadmill perturbation trials
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 35648294

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg implanted into the socket
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control site (no simvastatin)
Number of subjects: 15
Study: 33431491

Group type: EXPERIMENTAL
Intervention: 30 mg of CNM-Au8 once daily for 36 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 36239783

Group type: EXPERIMENTAL
Intervention: TEAS combined with PPI for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: PPI alone for 12 weeks
Number of subjects: 70
Study: 32935199

Group type: EXPERIMENTAL
Intervention: High-risk group (serum levels of Ti, Al, V)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-risk group (control)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Comparison between high-risk and low-risk groups
Number of subjects: 19
Study: 32998143

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg monotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg monotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Eplerenone/Ramipril 50/10 mg combination therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 36123724

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate injection (2 ml)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Saline injection (2 ml)
Number of subjects: 180
Study: 33045140

Group type: EXPERIMENTAL
Intervention: Intranasal capsaicin 0.1mM
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 32173018

Group type: EXPERIMENTAL
Intervention: Gradual weaning protocol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Abrupt weaning protocol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High concentrate intake (>350 g/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low concentrate intake (≤350 g/d)
Number of subjects: 36
Study: 35243319

Group type: EXPERIMENTAL
Intervention: Parotid gland irradiation (2x6 Gy with one week interval)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Submandibular gland irradiation (2x6 Gy with one week interval)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham irradiation (placebo)
Number of subjects: 31
Study: 32015491

Group type: EXPERIMENTAL
Intervention: ≥ 12% VAF TP53 mutations
Number of subjects: 499

Group type: COMPARATOR
Intervention: <12% VAF TP53 mutations
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Biallelic BIRC3 lesions (mutation and deletion)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Mutated MAPK-ERK genes
Number of subjects: 499
Study: 34489274

Group type: EXPERIMENTAL
Intervention: Investigational regimens in TB-PRACTECAL trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venous blood samples collected at various time points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sputum samples collected at baseline and monthly to week 24
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full blood count, urea and electrolytes, liver function tests, lipase, ECGs and ophthalmology examinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PK and PKPD models developed for each drug
Number of subjects: 0
Study: 34516535

Group type: EXPERIMENTAL
Intervention: Inflammation-adjusted ferritin concentrations using a higher ferritin cut-off point (<30 g/L)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Inflammation-adjusted ferritin concentrations excluding subjects with inflammation (C-reactive protein >5 mg/L or a1-acid glycoprotein >1 g/L)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Inflammation-adjusted ferritin concentrations using a mathematical correction factor based on C-reactive protein or a1-acid glycoprotein
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Inflammation-adjusted ferritin concentrations using regression correction method proposed by the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia Group
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Unadjusted prevalence of iron deficiency
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Proportion of children with inflammation according to C-reactive protein concentrations >5 mg/L
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Proportion of children with inflammation according to a1-acid glycoprotein concentrations >1 g/L
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Percentage of children with high concentrations of at least one inflammatory biomarker
Number of subjects: 1375
Study: 32217654

Group type: COMPARATOR
Intervention: INBUILD trial (n=331)
Number of subjects: 754

Group type: COMPARATOR
Intervention: INPULSIS trials (n=423)
Number of subjects: 754
Study: 35840306

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic administration 1 week prior to tissue culture collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic administration 3 days prior to tissue culture collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic administration 1 day prior to tissue culture collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic administration 1 day after tissue culture collection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease-related markers (white blood cell count, C reactive protein, erythrocyte sedimentation rate, vital signs, length of hospital stay)
Number of subjects: 0
Study: 33549078

Group type: EXPERIMENTAL
Intervention: Vaginal palpation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Transabdominal ultrasound
Number of subjects: 65
Study: 35301929

Group type: EXPERIMENTAL
Intervention: NO3‐‐rich beetroot juice (BR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NO3‐‐depleted beetroot juice (PL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON; water)
Number of subjects: 12
Study: 32331584

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 44
Study: 36322844

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide
Number of subjects: 587

Group type: COMPARATOR
Intervention: Standard pediatric regimen of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide
Number of subjects: 587
Study: 34431929

Group type: EXPERIMENTAL
Intervention: Floral therapy (Five Flower floral essence)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 164
Study: 32196393

Group type: EXPERIMENTAL
Intervention: Semi-occluded water resistance ventilation mask (30 min session)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional water resistance approach (30 min session)
Number of subjects: 24
Study: 35287713

Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) - 5:2 diet
Number of subjects: 147

Group type: COMPARATOR
Intervention: Continuous Calorie Restriction (CCR)
Number of subjects: 147
Study: 33567733

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) enriched with extra-virgin olive oil or nuts
Number of subjects: 4189

Group type: COMPARATOR
Intervention: Control diet (low-fat diet)
Number of subjects: 4189
Study: 34785108

Group type: EXPERIMENTAL
Intervention: Yindan Jiedu granules (YDJDG)
Number of subjects: 262
Study: 32213777

Group type: EXPERIMENTAL
Intervention: Silicone stent placement
Number of subjects: 78

Group type: COMPARATOR
Intervention: No stent
Number of subjects: 78
Study: 34044375

Group type: EXPERIMENTAL
Intervention: Transbond XT containing 1% chitosan NPs and 1% TiO2 NPs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transbond XT (control group)
Number of subjects: 24
Study: 32542040

Group type: EXPERIMENTAL
Intervention: Earlier age at menarche
Number of subjects: 114883

Group type: EXPERIMENTAL
Intervention: Age at first sexual intercourse
Number of subjects: 114883
Study: 35962639

Group type: EXPERIMENTAL
Intervention: Midazolam/Ketamine (30 to 50 μg/kg and 0.25 to 1 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Propofol/Fentanyl (0.5 to 1 mg/kg and 0.5 to 1 mg/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Midazolam/Ketamine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Propofol/Fentanyl
Number of subjects: 17
Study: 34821547

Group type: EXPERIMENTAL
Intervention: Mifepristone plus misoprostol
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo plus misoprostol
Number of subjects: 711
Study: 35389583

Group type: EXPERIMENTAL
Intervention: Intense pulsed light and radiofrequency therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 9
Study: 34008857

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 35171682

Group type: EXPERIMENTAL
Intervention: Children who died (n = 92)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Children who survived (n = 92)
Number of subjects: 184
Study: 34029160

Group type: EXPERIMENTAL
Intervention: Metsulfuron applied at 0 days before sowing (DBS)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Metsulfuron applied at 15 DBS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Metsulfuron applied at 30 DBS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Metsulfuron applied at 45 DBS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Metsulfuron applied at 14 to 28 days after emergence (DAE)
Number of subjects: 4
Study: 35220312

Group type: EXPERIMENTAL
Intervention: Propolis alone (1,000 mg/day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Propolis (1,000 mg/day) plus melatonin (20 mg/day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Melatonin alone (20 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 55
Study: 32746654

Group type: EXPERIMENTAL
Intervention: NutrInform Battery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nutri-Score
Number of subjects: 200
Study: 33091589

Group type: EXPERIMENTAL
Intervention: CBT‐I&N followed by CPT
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: CPT followed by CBT‐I&N
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: CPT followed by CPT
Number of subjects: 222
Study: 36411426

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (0.4 ml/kg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (0.8 ml/kg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Both groups (0.25% and 0.125% bupivacaine)
Number of subjects: 74
Study: 32769457

Group type: EXPERIMENTAL
Intervention: H&P 360 intervention with brief written instructions
Number of subjects: 159

Group type: COMPARATOR
Intervention: Traditional H&P without additional instructions
Number of subjects: 159
Study: 34126446

Group type: EXPERIMENTAL
Intervention: Half-strength STP sludge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-strength STP sludge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Freshwater
Number of subjects: 0

Group type: COMPARATOR
Intervention: Seawater
Number of subjects: 0

Group type: COMPARATOR
Intervention: Half-strength seawater
Number of subjects: 0
Study: 34328346

Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACEs)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Exercise intervention (8 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: SIRT1
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD)
Number of subjects: 42
Study: 34887261

Group type: EXPERIMENTAL
Intervention: trilaciclib prior to GCb (days 1, 8)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: trilaciclib (days 1, 8) and trilaciclib prior to GCb (days 2, 9)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: trilaciclib prior to GCb (days 1, 8) and trilaciclib (days 1, 8)
Number of subjects: 102

Group type: COMPARATOR
Intervention: GCb (days 1, 8)
Number of subjects: 102
Study: 35113903

Group type: EXPERIMENTAL
Intervention: Heated humidified O2
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cold humidified O2
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard O2
Number of subjects: 66
Study: 34786388

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenous single dose one hour before TACE
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32601879

Group type: EXPERIMENTAL
Intervention: Cam impingement morphology
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tegner Score, Harris Hip Score (HHS), and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Number of subjects: 51
Study: 34870584

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sleep Hygiene
Number of subjects: 56
Study: 35080055

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using Oculus GO with three-dimensional specific software content
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sham VR
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no VR)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: VR
Number of subjects: 96
Study: 33957506

Group type: EXPERIMENTAL
Intervention: Mindfulness-based programme (MBP)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Mindfulness-based programme + Virtual Reality (MBP + VR)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Relaxation (active control)
Number of subjects: 280
Study: 32871696

Group type: EXPERIMENTAL
Intervention: VRET
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 43
Study: 35627652

Group type: EXPERIMENTAL
Intervention: Heart to Heart Card Game
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study: 33098211

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg orally once daily for 3 months (n = 12)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 157

Group type: COMPARATOR
Intervention: Moderate to severe depressive symptoms (PHQ-9)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Clinical depression based on interview
Number of subjects: 157
Study: 35240861

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 623

Group type: COMPARATOR
Intervention: Endovascular treatment only (Control)
Number of subjects: 623
Study: 32920808

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4328

Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban (HDER)
Number of subjects: 4328

Group type: EXPERIMENTAL
Intervention: Lower dose edoxaban (LDER)
Number of subjects: 4328
Study: 35281950

Group type: EXPERIMENTAL
Intervention: PRP+VSD treatment (group D)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Other algorithms
Number of subjects: 84
Study: 32565319

Group type: EXPERIMENTAL
Intervention: External radiation boost (5 × 3 Gy) followed by standard pelvic chemoradiation (25 × 2 Gy with concurrent capecitabine)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard pelvic chemoradiation (25 × 2 Gy with concurrent capecitabine) without boost
Number of subjects: 128